Abivax S.A. Stock
Price
Target price
€101.60
€101.60
2.330%
2.3
2.330%
-
02.04.26 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
Abivax S.A. gained 2.330% today.
So far the community has only identified positive things for Abivax S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Abivax S.A. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | 2.330% | - | - | - | - | - | - |
| Nanobiotix | -1.630% | 1.304% | 2.836% | 772.354% | 42.408% | 752.665% | 104.974% |
| Innate Pharma | 3.780% | 7.263% | -19.101% | -35.208% | -24.706% | -56.757% | -68.932% |
| Poxel S.A. | -24.560% | 20.343% | 6.641% | 15.638% | 17.573% | -59.334% | -95.781% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
EQS-News: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
EQS-News: Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
EQS-News: Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026